FDA To Warn About Post-COVID Vax Guillain-Barré Syndrome

The FDA will issue a warning that Johnson & Johnson's COVID-19 vaccine may trigger Guillain-Barré syndrome (GBS) in a small number of people, an agency spokesperson told MedPage Today on Monday. Of the 12.5 million Americans who received this vaccine, about 100 people reported having GBS in the Vaccine Adverse Event Reporting System (VAERS). Of these reports, 95 of them were serious and required hospitalization, and there was one reported death, an FDA official said.